thiotepa has been researched along with Cholera Infantum in 6 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0." | 9.08 | Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995) |
| "Thirty-eight women with responsive metastatic breast cancer received high-dose cyclophosphamide (3 to 6 g/m2 over 4 days), thiotepa (400 to 800 mg/m2), and novobiocin (0." | 5.08 | Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. ( Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995) |
| "Women with stage IV breast cancer who had achieved a CR or PR during conventional chemotherapy were enrolled in a phase II trial of high-dose cyclophosphamide 7500 mg/m2 and thiotepa 675 mg/m2 (C+T) followed within 180 days by high-dose melphalan (M) 140 mg/m2." | 2.68 | Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. ( Bitran, JD; Hanauer, S; Harris, E; Johnson, L; Kempler, J; Klein, L; Martinec, J; Samuels, B; White, W, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreri, AJ | 1 |
| Cwynarski, K | 1 |
| Pulczynski, E | 1 |
| Ponzoni, M | 1 |
| Deckert, M | 1 |
| Politi, LS | 1 |
| Torri, V | 1 |
| Fox, CP | 1 |
| Rosée, PL | 1 |
| Schorb, E | 1 |
| Ambrosetti, A | 1 |
| Roth, A | 1 |
| Hemmaway, C | 1 |
| Ferrari, A | 1 |
| Linton, KM | 1 |
| Rudà, R | 1 |
| Binder, M | 1 |
| Pukrop, T | 1 |
| Balzarotti, M | 1 |
| Fabbri, A | 1 |
| Johnson, P | 1 |
| Gørløv, JS | 1 |
| Hess, G | 1 |
| Panse, J | 1 |
| Pisani, F | 1 |
| Tucci, A | 1 |
| Stilgenbauer, S | 1 |
| Hertenstein, B | 1 |
| Keller, U | 1 |
| Krause, SW | 1 |
| Levis, A | 1 |
| Schmoll, HJ | 1 |
| Cavalli, F | 1 |
| Finke, J | 1 |
| Reni, M | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| McCoy, AG | 1 |
| Smith, EP | 1 |
| Atkinson, ME | 1 |
| Baranski, B | 1 |
| Kahl, BS | 1 |
| Juckett, M | 1 |
| Mitchell, T | 1 |
| Gangnon, R | 1 |
| Longo, WL | 1 |
| Kennedy, MJ | 1 |
| Armstrong, DK | 1 |
| Huelskamp, AM | 1 |
| Ohly, K | 1 |
| Clarke, BV | 1 |
| Colvin, OM | 1 |
| Grochow, LB | 1 |
| Chen, TL | 1 |
| Davidson, NE | 1 |
| Bitran, JD | 1 |
| Samuels, B | 1 |
| Klein, L | 1 |
| Hanauer, S | 1 |
| Johnson, L | 1 |
| Martinec, J | 1 |
| Harris, E | 1 |
| Kempler, J | 1 |
| White, W | 1 |
| Perez-Ceballos, E | 1 |
| Vallejo, C | 1 |
| Cano, H | 1 |
| Ayala, F | 1 |
| Martínez, F | 1 |
| Moraleda, J | 1 |
| Vicente, V | 1 |
| De Giorgi, U | 1 |
| Rosti, G | 1 |
| Papiani, G | 1 |
| Marangolo, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra[NCT01011920] | Phase 2 | 126 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thiotepa and Cholera Infantum
| Article | Year |
|---|---|
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical T | 2002 |
4 trials available for thiotepa and Cholera Infantum
| Article | Year |
|---|---|
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System | 2016 |
A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etoposide; Female; | 2004 |
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 1995 |
Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1996 |
1 other study available for thiotepa and Cholera Infantum
| Article | Year |
|---|---|
Fatal upper and lower gastrointestinal cytomegalovirus disease following autologous peripheral blood stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytomegalovirus Infections; Fatal Outcome; | 2001 |